MabThera Drug Utilisation Study and Patient Alert Card Evaluation in Non-Oncology Patients in Europe: An Infusion Centre-Based Approach

Trial Profile

MabThera Drug Utilisation Study and Patient Alert Card Evaluation in Non-Oncology Patients in Europe: An Infusion Centre-Based Approach

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 17 Jul 2017

At a glance

  • Drugs Rituximab (Primary)
  • Indications Microscopic polyangiitis; Nephrotic syndrome; Neuromyelitis optica; Pemphigus vulgaris; Primary biliary cirrhosis; Rheumatoid arthritis; Transplant rejection; Wegener's granulomatosis
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 12 Apr 2017 Planned End Date changed from 1 Feb 2017 to 31 Aug 2017.
    • 12 Apr 2017 Planned primary completion date changed from 1 Feb 2017 to 31 Aug 2017.
    • 04 May 2016 Planned End Date changed from 1 Oct 2017 to 1 Feb 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top